A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult
patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) after one or two
prior lines of systemic therapy for advanced/metastatic disease as measured by overall
response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.